VA and Medicare Reimbursement for Ketamine/Esketamine
The VA reimburses ketamine infusion and intranasal esketamine for treatment-resistant depression (TRD) after failure of at least 2 adequate antidepressant trials, and for acute suicidal ideation in major depressive disorder (MDD); Medicare covers FDA-approved intranasal esketamine (Spravato) for these same indications, but does NOT routinely cover off-label IV ketamine infusion.
VA-Covered Diagnoses
Based on the 2022 VA/DoD Clinical Practice Guidelines, the VA provides reimbursement for:
1. Treatment-Resistant Depression (TRD)
- Specific criteria: Patients with MDD who have failed at least 2 adequate trials of antidepressant medications 1
- Both ketamine infusion and esketamine are covered as treatment options 1
- Must be used either as monotherapy or in conjunction with an ongoing oral antidepressant 1
- Not approved as first-line treatment—reserved specifically for patients where previous therapies have failed or were not tolerated 1
2. Major Depressive Disorder with Acute Suicidal Ideation or Behavior
- Ketamine infusion is supported as adjunctive treatment for short-term reduction in suicidal ideation 2, 1
- Must be used in conjunction with an oral antidepressant 2
- The 2024 VA/DoD suicide prevention guideline specifically endorses this indication 2
3. Schizophrenia with Suicide Risk
- The 2024 guidelines mention pharmacologic treatments including ketamine infusion for suicide risk management in patients with schizophrenia 2
Medicare Coverage
Medicare Part D and traditional Medicare coverage differs significantly:
Covered:
- Intranasal esketamine (Spravato) for FDA-approved indications 3:
- Treatment-resistant depression in adults (as monotherapy or with oral antidepressant)
- Depressive symptoms in adults with MDD and acute suicidal ideation or behavior (with oral antidepressant)
NOT Typically Covered:
- Off-label IV ketamine infusion is generally not reimbursed by Medicare, as it lacks FDA approval for depression
- Patients seeking IV ketamine typically pay out-of-pocket or use VA benefits if eligible
Critical Implementation Requirements
For Esketamine (Both VA and Medicare):
- REMS program participation required 3
- Mandatory 2-hour post-administration monitoring 1, 3
- Healthcare setting and pharmacy must be certified 1
- Blood pressure assessment before and after administration 3
Treatment Duration Expectations:
- TRD: Therapeutic benefit should be evaluated at end of 4-week induction phase to determine continuation 3
- Acute suicidal ideation: Evidence of benefit evaluated after 4 weeks; treatment beyond 4 weeks has not been systematically evaluated 3
Important Caveats
Contraindications that would prevent reimbursement 3:
- Aneurysmal vascular disease (aortic, intracranial, peripheral arterial)
- Arteriovenous malformation
- Intracerebral hemorrhage
- Hypersensitivity to ketamine or esketamine
Documentation requirements for approval:
- Must document failure of at least 2 adequate antidepressant trials for TRD 1
- For suicide risk: documented acute suicidal ideation or behavior with MDD diagnosis 2
- Ongoing oral antidepressant therapy (required for esketamine approval) 1, 3
Key limitation: The effectiveness of esketamine in preventing suicide or reducing suicidal ideation/behavior has NOT been established, despite its approval for this indication 1, 3. This represents an evidence-practice gap that clinicians should discuss with patients.
The VA system offers broader access to both ketamine formulations compared to Medicare, which strictly limits coverage to the FDA-approved intranasal esketamine product with its associated REMS requirements.